Edition:
United Kingdom

Orion Oyj (ORNBV.HE)

ORNBV.HE on Helsinki Stock Exchange

32.99EUR
19 Jan 2018
Change (% chg)

€0.40 (+1.23%)
Prev Close
€32.59
Open
€32.62
Day's High
€33.50
Day's Low
€32.61
Volume
680,588
Avg. Vol
450,880
52-wk High
€58.50
52-wk Low
€29.72

Latest Key Developments (Source: Significant Developments)

Orion To Launch Negotiations That May Result In Personnel Reductions
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Orion Oyj ::ORION TO RENEW OPERATING MODEL OF ITS LABORATORIES.‍COMPANY WILL LAUNCH CO-OPERATION NEGOTIATIONS IN LABORATORY OPERATIONS​.‍ORION DIAGNOSTICA'S LABORATORIES WILL NOT BE PART OF NEGOTIATIONS.​.IS TO FURTHER STREAMLINE OPERATING MODEL FOR LABORATORIES AND DEVELOP PRODUCTIVITY BY CHANGING OPERATING MODEL.​.‍NEGOTIATIONS MAY RESULT IN PERSONNEL REDUCTIONS OF A MAXIMUM OF 40 PERSONS.​.  Full Article

Peptonic Medical Enters Tech Transfer Agreement With Orion
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Peptonic Medical Ab ::PEPTONIC MEDICAL AND ORION ENTER VAGIVITAL™ TECH TRANSFER AGREEMENT.‍ENTERED A TECH TRANSFER AGREEMENT WITH ORION CORPORATION, HEADQUARTERED IN ESPOO, FINLAND​.‍UNDER AGREEMENT, TWO COMPANIES WILL EXCHANGE INFORMATION AND COLLABORATE.- ‍TO PREPARE FOR COMMERCIAL MANUFACTURE OF VAGIVITAL™ - A PRODUCT THAT PEPTONIC PLANS TO LAUNCH IN 2018​.‍COMPANIES SIGNED TERMS SHEET FOR A FINAL AGREEMENT REGARDING COMMERCIAL MANUFACTURE OF VAGIVITAL™​.  Full Article

Orion Q3 EBIT EUR 56.4‍​ million, misses expectations
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - ORION OYJ :‍OUTLOOK ESTIMATE FOR 2017 REMAINS UNCHANGED.​.Q3 SALES EUR ‍252.7​ MILLION (REUTERS POLL EUR 266 MILLION).‍OUTLOOK ESTIMATE FOR 2017 REMAINS UNCHANGED.​.Q3 EBIT EUR 56.4‍​ MILLION (REUTERS POLL EUR 70.5 MILLION).  Full Article

Orion Oyj and Menarini Group enter into collaboration agreement
Friday, 2 Sep 2016 

Orion Oyj : Says the company and Menarini Group collaborate on budesonide-formoterol Easyhaler combination product for asthma and COPD . Agreement is for co-marketing of Easyhaler in Germany, Italy, Spain, and Portugal . Parties have also agreed on exclusive license and distribution arrangement in France and Turkey . Parties will market budesonide-formoterol Easyhaler under their own brands .Menarini Group is Italian pharmaceutical company.  Full Article

Orion Q2 EBIT beats expectations at EUR 83.5 million
Tuesday, 19 Jul 2016 

Orion Oyj : Q2 EBIT 83.5 million euros ($92.4 million) (Reuters poll 74.4 million euros) . Q2 sales 273.1 million euros (Reuters poll 266 million euros) . Estimates that in 2016 net sales will be slightly higher than in 2015 .2016 operating profit excluding possible capital gains is estimated to exceed 270 million euros.  Full Article

Orion Corporation and Asahi Kasei enters into global strategic collaboration
Wednesday, 22 Jun 2016 

Orion Oyj : Says that it has entered into a global strategi collaboration agreement with Japanese Asahi Kasei Pharma for the discovery, development and commercialisation of assets in pain management . Agreement comprises a total of four discovery phase candidates, two from Asahi Kasei and two from Orion .Collaboration allows both companies to exclusively license others' development-ready programs at pre-determined stages.  Full Article

Orion completes share buyback
Thursday, 16 Jun 2016 

Orion Oyj : Said on Wednesday it completed share acquisitions . Bought total of 500,000 own B shares at average price of about 33.5319 euros per share . Total purchase price was 16,765,946.50 euros ($18.89 million) .It holds now total of 783,366 own B shares corresponding to about 0.55 pct of total number of shares and 0.09 pct of votes.  Full Article

Orion upgrades full-year outlook for 2016
Wednesday, 15 Jun 2016 

Orion Oyj : Orion upgrades full-year outlook for 2016 . Net sales are estimated to be slightly higher than in 2015 . Now sees 2016 operating profit without potential capital gains is estimated to exceed 270 million euros (operating profit was 267 million euros in 2015 .Shares rise 4 percent.  Full Article

Orion and Bayer start new phase III study of prostate cancer drug
Friday, 3 Jun 2016 

Orion Oyj : Says Orion and Bayer expand clinical development program for ODM-201 and initiate a new phase III study Arasens in patients with metastatic hormone-sensitive prostate cancer . Says new the study will evaluate the safety and efficacy of the compound in combination with standard androgen deprivation therapy (ADT) and the chemotherapy docetaxel in men with newly diagnosed metastatic hormone-sensitive prostate cancer .Says new trial is expected to start the enrolment of patients towards the end of 2016.  Full Article

Finland's Orion to buy back shares
Wednesday, 27 Apr 2016 

Orion Oyj:Decision by the board of directors to acquire own shares.500,000 class B shares will be acquired, acquisition will be started at earliest on 4 May and it can continue until further notice.  Full Article

BRIEF-Orion To Launch Negotiations That May Result In Personnel Reductions

* ‍COMPANY WILL LAUNCH CO-OPERATION NEGOTIATIONS IN LABORATORY OPERATIONS​